CompletedNCT04470050
BXCL501 for Symptoms of Opioid Withdrawal
About this title
Read the official source — NCT04470050Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Miami Lakes and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: June 9, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 225
- Sponsor
- BioXcel Therapeutics Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04470050
- Official title
Show the full official title
A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on Opioids
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Miami Lakes · Marlton · New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is BioXcel Therapeutics Inc.
Did this study involve medication?
Yes. The study involved medication, including Dexmedetomidine and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
